Posted 29th October 2018 by Jane Williams
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease and is increasing in prevalence as an etiology for end-stage liver disease and also hepatocellular carcinoma. NASH is often a silent disease and many patients have undiagnosed NASH for several years without experiencing any symptoms.
Posted 12th June 2018 by Jane Williams
If I were to tell you that there was a multi-million pound race to help more than 1 billion people – you would call me crazy, but believe it or not, it’s actually true! In recognition of International NASH Day, I’m asking what’s the big hold up when it comes to treating NASH?
Posted 23rd May 2018 by Jane Williams
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.
Posted 12th February 2018 by Jane Williams
Silent killers such as diabetes, high cholesterol and hypertension have been well discussed for many years. While non-medical professionals may not understand the pathophysiology of these diseases, most people can appreciate that they are harmful conditions which require treatment. Worldwide, nonalcoholic fatty liver disease (NAFLD) is estimated to affect more than 1 billion people; so why is nobody talking about it?
Posted 15th January 2018 by Jane Williams
The effects of lifestyle interventions as a baseline therapy for the treatment of NASH are well accepted. However, there is a high degree of frustration when it comes to recommending and implementing lifestyle changes. Large interventional studies in the field of metabolic disease are largely negative with regards to long-term outcomes.
Posted 15th December 2017 by Jane Williams
Multifactorial diseases require a safe, multifunctional and integrated approach to treatment. Based on this recognition, a new class of therapeutics, called Defined Amino Acid Compositions (DAACs™), are being pioneered by Axcella Health.